FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease

Daigo Hashimoto, Shoji Asakura, Ken-ichi Matsuoka, Yukimi Sakoda, Motoko Koyama, Kazutoshi Aoyama, Mitsune Tanimoto, Teshima Takanori

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

FTY720 is a novel immunosuppressant that improves the outcomes after solid organ and one marrow transplantation (BMT) due to the sequestration of T cells into LN. We tested the hypothesis that the sequestration of donor T cells in LN by FTY720 would enhance their interaction with host APC, thus causing a greater degree of activation-induced apoptosis of alloreactive T cells, and thereby resulting in a reduction of graft-vs.-host disease (GVHD). The short-term administration of FTY720 improved the recipient survival after allogeneic BMT. FTY720 treatment facilitated a rapid contraction of the donor T cell pool in association with an increased degree of apoptosis of donor T cells. The donor T cell reactivity to host alloantigens was diminished in host's LN and adoptive transfer of donor T cells isolated from LN of FTY720-treated recipients of allogeneic BMT induced less severe GVHD in secondary recipients than the transfer from controls. Caspase-dependent apoptosis was involved in this mechanism because FTY720-induced protection was abrogated when a pan-caspase inhibitor was administered. These findings thus demonstrate the presence of a novel mechanism by which FTY720 modulates the allogeneic T cell responses: namely, by the induction of activation-induced apoptosis of alloreactive T cells in LN.

Original languageEnglish
Pages (from-to)271-281
Number of pages11
JournalEuropean Journal of Immunology
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Graft vs Host Disease
Apoptosis
T-Lymphocytes
Fingolimod Hydrochloride
Caspase Inhibitors
Isoantigens
Adoptive Transfer
Immunosuppressive Agents
Caspases
Transplantation
Bone Marrow
Transplants

Keywords

  • Animal models
  • Apoptosis
  • Transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. / Hashimoto, Daigo; Asakura, Shoji; Matsuoka, Ken-ichi; Sakoda, Yukimi; Koyama, Motoko; Aoyama, Kazutoshi; Tanimoto, Mitsune; Takanori, Teshima.

In: European Journal of Immunology, Vol. 37, No. 1, 01.2007, p. 271-281.

Research output: Contribution to journalArticle

Hashimoto, D, Asakura, S, Matsuoka, K, Sakoda, Y, Koyama, M, Aoyama, K, Tanimoto, M & Takanori, T 2007, 'FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease', European Journal of Immunology, vol. 37, no. 1, pp. 271-281. https://doi.org/10.1002/eji.200636123
Hashimoto, Daigo ; Asakura, Shoji ; Matsuoka, Ken-ichi ; Sakoda, Yukimi ; Koyama, Motoko ; Aoyama, Kazutoshi ; Tanimoto, Mitsune ; Takanori, Teshima. / FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. In: European Journal of Immunology. 2007 ; Vol. 37, No. 1. pp. 271-281.
@article{d1c163c7ddc74ed293f35caa1e91352a,
title = "FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease",
abstract = "FTY720 is a novel immunosuppressant that improves the outcomes after solid organ and one marrow transplantation (BMT) due to the sequestration of T cells into LN. We tested the hypothesis that the sequestration of donor T cells in LN by FTY720 would enhance their interaction with host APC, thus causing a greater degree of activation-induced apoptosis of alloreactive T cells, and thereby resulting in a reduction of graft-vs.-host disease (GVHD). The short-term administration of FTY720 improved the recipient survival after allogeneic BMT. FTY720 treatment facilitated a rapid contraction of the donor T cell pool in association with an increased degree of apoptosis of donor T cells. The donor T cell reactivity to host alloantigens was diminished in host's LN and adoptive transfer of donor T cells isolated from LN of FTY720-treated recipients of allogeneic BMT induced less severe GVHD in secondary recipients than the transfer from controls. Caspase-dependent apoptosis was involved in this mechanism because FTY720-induced protection was abrogated when a pan-caspase inhibitor was administered. These findings thus demonstrate the presence of a novel mechanism by which FTY720 modulates the allogeneic T cell responses: namely, by the induction of activation-induced apoptosis of alloreactive T cells in LN.",
keywords = "Animal models, Apoptosis, Transplantation",
author = "Daigo Hashimoto and Shoji Asakura and Ken-ichi Matsuoka and Yukimi Sakoda and Motoko Koyama and Kazutoshi Aoyama and Mitsune Tanimoto and Teshima Takanori",
year = "2007",
month = "1",
doi = "10.1002/eji.200636123",
language = "English",
volume = "37",
pages = "271--281",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease

AU - Hashimoto, Daigo

AU - Asakura, Shoji

AU - Matsuoka, Ken-ichi

AU - Sakoda, Yukimi

AU - Koyama, Motoko

AU - Aoyama, Kazutoshi

AU - Tanimoto, Mitsune

AU - Takanori, Teshima

PY - 2007/1

Y1 - 2007/1

N2 - FTY720 is a novel immunosuppressant that improves the outcomes after solid organ and one marrow transplantation (BMT) due to the sequestration of T cells into LN. We tested the hypothesis that the sequestration of donor T cells in LN by FTY720 would enhance their interaction with host APC, thus causing a greater degree of activation-induced apoptosis of alloreactive T cells, and thereby resulting in a reduction of graft-vs.-host disease (GVHD). The short-term administration of FTY720 improved the recipient survival after allogeneic BMT. FTY720 treatment facilitated a rapid contraction of the donor T cell pool in association with an increased degree of apoptosis of donor T cells. The donor T cell reactivity to host alloantigens was diminished in host's LN and adoptive transfer of donor T cells isolated from LN of FTY720-treated recipients of allogeneic BMT induced less severe GVHD in secondary recipients than the transfer from controls. Caspase-dependent apoptosis was involved in this mechanism because FTY720-induced protection was abrogated when a pan-caspase inhibitor was administered. These findings thus demonstrate the presence of a novel mechanism by which FTY720 modulates the allogeneic T cell responses: namely, by the induction of activation-induced apoptosis of alloreactive T cells in LN.

AB - FTY720 is a novel immunosuppressant that improves the outcomes after solid organ and one marrow transplantation (BMT) due to the sequestration of T cells into LN. We tested the hypothesis that the sequestration of donor T cells in LN by FTY720 would enhance their interaction with host APC, thus causing a greater degree of activation-induced apoptosis of alloreactive T cells, and thereby resulting in a reduction of graft-vs.-host disease (GVHD). The short-term administration of FTY720 improved the recipient survival after allogeneic BMT. FTY720 treatment facilitated a rapid contraction of the donor T cell pool in association with an increased degree of apoptosis of donor T cells. The donor T cell reactivity to host alloantigens was diminished in host's LN and adoptive transfer of donor T cells isolated from LN of FTY720-treated recipients of allogeneic BMT induced less severe GVHD in secondary recipients than the transfer from controls. Caspase-dependent apoptosis was involved in this mechanism because FTY720-induced protection was abrogated when a pan-caspase inhibitor was administered. These findings thus demonstrate the presence of a novel mechanism by which FTY720 modulates the allogeneic T cell responses: namely, by the induction of activation-induced apoptosis of alloreactive T cells in LN.

KW - Animal models

KW - Apoptosis

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=33846368457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846368457&partnerID=8YFLogxK

U2 - 10.1002/eji.200636123

DO - 10.1002/eji.200636123

M3 - Article

C2 - 17154260

AN - SCOPUS:33846368457

VL - 37

SP - 271

EP - 281

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 1

ER -